Dr. Rahmuddin khan | Pharmaceutics Awards | Best Researcher Award

Posted on by ScienceFather

Dr. Rahmuddin khan | Pharmaceutics Awards | Best Researcher Award

Dr. Rahmuddin khan, jamia hamdard, India

Dr. Rahmuddin is a skilled pharmaceutics researcher specializing in nano-based drug delivery systems for topical diseases, with a primary focus on psoriasis. Currently affiliated with the Nanomedicine Lab at Jamia Hamdard, New Delhi, he has a rich background in developing functional excipients and enhancing drug solubility through novel formulations. His academic path, from a Bachelorā€™s to a Ph.D. in Pharmaceutics at Jamia Hamdard, has cultivated his expertise across several scientific domains. Rahmuddinā€™s research includes hands-on experience with regulatory safety, non-clinical assessments, and industry-sponsored projects involving fulvic acid-based nanoformulations. Known for his analytical thinking, scientific writing, and mentorship, he has published extensively in reputable journals, showcasing advancements in nanoemulsion gels for conditions like psoriasis and tuberculosis. His collaborative work with New Zealand Fulvic Acid Limited and Reckitt Benckiser demonstrates his commitment to bridging industry with academic research for innovative therapeutic solutions.

Professional Profile:

Google Scholar

Suitability for the Best Researcher Award:

Dr. Rahmuddin is a highly deserving candidate for the Best Researcher Award due to his significant contributions to the field of pharmaceutics, particularly in the area of nano-based drug delivery systems for topical diseases such as psoriasis. His innovative research focuses on enhancing drug solubility and improving the effectiveness of topical treatments through novel formulations, including nanoemulsion gels. Dr. Rahmuddinā€™s academic background, culminating in his Ph.D. from Jamia Hamdard, showcases his deep understanding of pharmaceutics and his dedication to advancing drug delivery systems. His work with industry collaborators like New Zealand Fulvic Acid Limited and Reckitt Benckiser demonstrates his ability to bridge the gap between academia and industry, driving practical solutions for complex medical challenges.

šŸŽ“Education :

Rahmuddin completed his entire academic journey in Pharmaceutics at Jamia Hamdard, New Delhi, earning his Ph.D. in 2023. His doctoral thesis, titled “Novel Functional Excipient Appended System for Psoriasis,” explored advanced nano-based drug delivery systems, aimed at enhancing topical treatments. Prior to his Ph.D., he completed his M.Pharm in 2018, where he focused on ā€œExploration of Novel Peat-Sourced Fulvic Acid for Solubility Improvement of BCS Class II Drugs.ā€ This research tackled the challenge of drug solubility by investigating natural compounds with pharmaceutical potential. He began his academic career with a B.Pharm in 2016 from the same institution, laying a solid foundation in pharmacy, pharmaceutics, and research methodologies. Throughout his academic journey, he developed strong technical expertise in drug formulation, excipient selection, and nano-delivery systems, equipping him with the necessary skills to innovate within the field of targeted drug delivery.

šŸ¢Experience :

Rahmuddin’s professional experience spans academia, industry collaboration, and regulatory roles. His most recent role as a Consumer Safety Assistant at Reckitt Benckiser (Mayā€“Oct 2024) involved ensuring regulatory compliance and conducting non-clinical safety assessments. During his M.Pharm, he worked as a Research Associate on an industry-sponsored project with New Zealand Fulvic Acid Limited, focused on fulvic acid-based nanoformulations, an experience that honed his skills in drug delivery for pharmaceutical applications. His extensive research as a Ph.D. candidate at Jamia Hamdard (Dec 2018ā€“Nov 2023) allowed him to specialize in topical drug delivery systems and provided opportunities to mentor M.Pharm and Ph.D. students. He has gained substantial laboratory experience, working with equipment like UV spectrophotometers, HPLC, tablet compression machines, and dissolution apparatuses, making him proficient in both theoretical knowledge and practical skills essential for pharmaceutical research.

šŸ…Awards and Honors :

Rahmuddin has received recognition for his work through various academic and industry-sponsored projects. Notably, his collaboration with New Zealand Fulvic Acid Limited on a project involving fulvic acid-based nanoformulations earned him significant acclaim, highlighting his contributions to innovative drug delivery research. His dedication to advancing drug solubility and effectiveness has been acknowledged within the academic community, where he has been a mentor and guide for students exploring solutions for complex diseases like psoriasis and tuberculosis. His publications in reputable journals, featuring targeted treatments and polysaccharide-based nano-drug delivery vehicles, showcase his commitment to expanding the applications of nano-based therapies. Through his professional experience and academic guidance, Rahmuddin continues to impact the field of pharmaceutics, bridging industry needs with academic insights to support advancements in the treatment of chronic diseases.

šŸ”¬Research Focus :

Rahmuddin’s research centers on the development of nano-based drug delivery systems for topical treatments, especially focusing on diseases like psoriasis. His work includes the creation of innovative excipients and nanoemulsion gels that improve drug solubility and targeted delivery, addressing issues faced with conventional formulations. In collaboration with New Zealand Fulvic Acid Limited, he has explored the pharmaceutical potential of fulvic acid for enhancing drug solubility, contributing to advancements in drug delivery systems. His technical skills encompass various analytical tools, including HPLC, UV spectrophotometry, and tablet compression machines, allowing him to design and assess complex formulations. Rahmuddinā€™s research portfolio spans a broad range of disease models beyond psoriasis, including acne and tuberculosis, exemplifying his commitment to leveraging nanotechnology for enhanced therapeutic outcomes. His contributions to scientific literature and mentorship to upcoming researchers further solidify his role as an innovative force in pharmaceutics.

Publication Top Notes:

  • “In vitro and in vivo investigation of a dual-targeted nanoemulsion gel for the amelioration of psoriasis”
    • Citations: 24
  • “A pharmaco-technical investigation of thymoquinone and peat-sourced fulvic acid nanoemulgel: a combination therapy”
    • Citations: 16
  • “Pharmacokinetic evaluation of fulvic acid-ketoconazole complexes: A validation and line extension study”
    • Citations: 7
  • “Neuroprotective effects of trigonelline in kainic acid-induced epilepsy: Behavioral, biochemical, and functional insights”
    • Citations: 5
  • “COVID-19 pandemic challenges and their management: A review of medicines, vaccines, patents and clinical trials with emphasis on psychological health issues”
    • Citations: 4

 

 

 

Assist. Prof. Dr. Mohamed skiba | Pharmaceutics Award | Best Innovation Award

Posted on by ScienceFather

Assist. Prof. Dr. Mohamed skiba | Pharmaceutics Award | Best Innovation Award

Assist. Prof. Dr. Mohamed skiba, University of rouen, France

Dr. Mohamed Skiba, is a French national and a distinguished pharmaceutical scientist. He is a lecturer at the Faculty of Medicine and Pharmacy in Rouen, where he leads the Pharmaceutical Team within the Galenic Group. Dr. Skiba earned his Ph.D. in Pharmaceutical Sciences from the University of Paris XI in 1994 and has been active in pharmaceutical research since 1990, focusing on cyclodextrin and drug vectorization. With over 140 international publications, 80 patents, and numerous contributions to books and congresses, he is a recognized expert in pharmaceutical technology. Dr. Skiba is also an active member of several scientific societies, including the French Society of Chemistry and the French Association of Teachers of Technological Pharmacy. He is fluent in French, English, and Arabic.

Professional Profile:

Orcid

Suitability for Best Innovation Award: Dr. Mohamed SKIBA

Dr. Mohamed Skibaā€™s extensive work in pharmaceutical sciences, particularly his research in drug formulation and cyclodextrin technologies, positions him as a strong candidate for the Best Innovation Award. His innovations, reflected in his numerous patents and publications, highlight his ability to drive pharmaceutical advancements with real-world applications. His leadership in academic and research institutions further amplifies his impact, making him a deserving recipient of this prestigious award.

šŸŽ“Education:

Dr. Mohamed Skiba holds a Ph.D. in Pharmaceutical Sciences, which he earned in 1994 from the University of Paris XI, Southern Paris. His academic journey also includes a Diploma of Thorough Studies in Pharmacotechnology and Biopharmacy (1990) from the University of Paris XI in ChĆ¢tenay-Malabry. In 1990, he obtained a Diploma in Veterinary Pharmaceuticals from the Faculty of Pharmacy, University of Clermont-Ferrand I. Additionally, Dr. Skiba completed advanced studies in pharmacology and electrophysiology with a Control of Research degree from the University of Poitiers in 1989. He also pursued studies in patent rights at the Faculty of Orsay, University of Paris-South, enriching his expertise in pharmaceutical and intellectual property matters.

šŸ¢Work Experience:

Dr. Mohamed Skiba has been a lecturer at the Faculty of Medicine and Pharmacy, University of Rouen, France, since 1998. In this role, he teaches courses in galenic and industrial galenic pharmacy to both undergraduate and graduate students, while also leading the Pharmaceutical Team within the Galenic Group. His professional experience includes serving as a trainee at the Central Pharmacy of the Hospitals of Paris (PCH) and working as an Associated AttachƩ in Toxicology and Clinical Pharmacology at the Hospital of Corbeil-Essonnes, further enhancing his expertise in pharmaceutical technology and clinical applications.

šŸ…Awards & Recognition:

Dr. Mohamed Skiba is a prolific contributor to the field of pharmaceutical technology, holding over 80 patents that highlight his innovative work. He has authored 140 international publications and contributed to 9 book chapters, making significant scholarly impacts. Additionally, Dr. Skiba has presented 71 communications at prestigious scientific congresses, sharing his research and advancements with the global scientific community.

šŸ”¬Research Focus:

Dr. Skiba’s research primarily centers on pharmaceutical technology, with a particular focus on cyclodextrin and drug vectorization. His work involves improving drug delivery systems, studying bio-polymeric materials, and developing innovative pharmaceutical formulations. He has been involved in numerous pharmaceutical research projects since 1990, contributing to the advancement of drug delivery and formulation technologies.

Publication Top Notes:

  • Powder Self-Emulsifying Drug Delivery System for Mitotane: In Vitro and In Vivo Evaluation
  • In vitro dissolution of encapsulated or dispersed vitamin E and cholesterol is correlated with preservation of refrigerated ovine sperm
  • Exploring the Therapeutic Potential of Algerian Propolis: GC/MS Profiling, Protective Inclusion Complex, and In Silico Evaluation Against SARSā€CoVā€2 Main Proteases
  • Development of a Novel Cyclodextrinā€“Chitosan Polymer for an Efficient Removal of Pharmaceutical Contaminants in Aqueous Solution

 

 

Prof. Franciska Erdo | Drug delivery Award | Best Researcher Award

Posted on by ScienceFather

Prof. Franciska Erdo | Drug delivery Award | Best Researcher Award

Prof. Franciska Erdo , PƔzmƔny PƩter Catholic University , Hungary

Franciska VidĆ”nĆ© Dr. Erdő, born on May 28, 1964, in Budapest, is a distinguished full professor and lab head at PĆ”zmĆ”ny PĆ©ter Catholic University, Faculty of Information Technology and Bionics. She holds a PhD in pharmacology from Semmelweis University and has extensive experience in both academic and research institutions, including the University of Tours, CharitĆ© Medizinische UniversitƤt in Berlin, and the Max-Planck Institute in Cologne. Her research focuses on drug research and development, evidenced by her numerous fellowships and scholarships. She has supervised over 31 graduate students and postdoctoral fellows and has been recognized for her teaching excellence. Dr. Erdő has also contributed significantly to scientific literature and education, particularly in the fields of molecular bionics and biomedical innovation.

Professional Profile:

Orcid

Education:

Franciska VidĆ”nĆ© Dr. Erdő earned her MSc in Pharmacy from Semmelweis University in 1987, graduating with top grades. She continued her education at the same institution, achieving a University Doctor degree in Pharmacology with summa cum laude honors in 1994. In 1997, she completed her PhD in Pharmacology, also with summa cum laude distinction, at Semmelweis University, Faculty of Pharmacy. Most recently, in 2019, she received her habilitation from PĆ”zmĆ”ny PĆ©ter Catholic University, Faculty of Information Technology and Bionics.

Work Experience:

Franciska VidĆ”nĆ© Dr. Erdő has held numerous esteemed positions throughout her career. Since 2024, she has been serving as a Full Professor and Lab Head at PĆ”zmĆ”ny PĆ©ter Catholic University, Faculty of Information Technology and Bionics. Prior to this, from 2019 to 2024, she was an Associate Professor and Lab Head at the same institution. She was also a Guest Researcher at the University of Tours, France, in 2022. From 2014 to 2019, she worked as a Senior Research Fellow and Lab Head at PĆ”zmĆ”ny PĆ©ter Catholic University. Her earlier roles include serving as a Senior Research Fellow and Lab Head at SOLVO Biotechnology from 2007 to 2014, and holding a scientific scholarship at CharitĆ© Medizinische UniversitƤt in Berlin, Germany, from 2005 to 2006. She also worked as a Senior Research Fellow at IVAX Drug Research Institute from 2003 to 2007 and held a Max Planck Fellowship at the Max-Planck Institute fĆ¼r neurologische Forschung in Cologne, Germany, from 2000 to 2003. Her earlier positions include Senior Research Fellow roles at Sanofi-Synthelabo Chinoin from 1997 to 2000 and Biorex R&D Co. from 1995 to 1997. She began her career as a Research Fellow at the Institute for Drug Research from 1990 to 1995 and as a Junior Research Fellow at the same institute from 1987 to 1990.

Publication Top Notes:

1.Fluid Dynamics Optimization of Microfluidic Diffusion Systems for Assessment of Transdermal Drug Delivery: An Experimental and Simulation Study

  • Journal: Scientia Pharmaceutica
  • Publication Date: June 2024

2. Progress in Topical and Transdermal Drug Delivery Researchā€”Focus on Nanoformulations

  • Journal: Pharmaceutics
  • Publication Date: June 2024

3. Transdermal Delivery of Ī±-Aminophosphonates as Semisolid Formulationsā€”An In Vitro-Ex Vivo Study

  • Journal: Pharmaceutics
  • Publication Date: May 2023